PLoS ONE · 2021 · 21 citations · 13 references
MedicineHematologyMolecular MedicineGene TherapyHematopathologyHemostasisAnemiaHematocrit RegulationIron DeficiencyIron Deficiency DisordersMyeloproliferative NeoplasmsDriver Mutation DiscoveryHematocrit EffectsJak2 MutationsMyeloproliferative Neoplasm TherapyMyeloproliferative Neoplasm TreatmentPhlebotomy TherapyProgenitor CellsThrombosis In Myeloproliferative Neoplasms
Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm resulting from an acquired driver mutation in the JAK2 gene of hematopoietic stem and progenitor cells resulting in the overproduction of mature erythrocytes and abnormally high hematocrit, in turn leading to thromboembolic complications. Therapeutic phlebotomy is the most common treatment to reduce the hematocrit levels and consequently decrease thromboembolic risk. Here we demonstrate that, by using the iron restrictive properties of the antisense oligonucleotides against Tmprss6 mRNA, we can increase hepcidin to achieve effects equivalent to therapeutic phlebotomy. We provide evidence that this less invasive approach could represent an additional therapeutic tool for the treatment of PV patients.
13
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature · 2005 · 3.5K citations
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli, Guido Finazzi, Giorgina Specchia et al. · New England Journal of Medicine · 2012 · 820 citations · Full text